RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
Interventional, prospective, randomized (1:1), controlled, open label, multicenter phase IIb
study in patients with advanced metastatic colorectal cancer. The scope of the trial is to
evaluate overall survival of either regimen (TAS102 +/- Ramucirumab) and evaluate safety and
tolerability.
Phase:
Phase 3
Details
Lead Sponsor:
IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest